ArticleEuropean journal of nuclear medicine and molecular imaging2020
Impact of
Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Prognostic value of PSMA PET/CT-Based local staging in predicting biochemical recurrence after radical prostatectomy.European journal of nuclear medicine and molecular imaging · 2026Article
- Comparison ofJournal of cancer research and clinical oncology · 2025Article
- Supraclavicular nodal metastasis at primary staging of prostate cancer usingEJNMMI reports · 2025Article
- Comparative Performance ofDiagnostics (Basel, Switzerland) · 2024Article
- Dual-time-point dynamicAnnals of nuclear medicine · 2024Article
- Comparison of Digital versus AnalogDiagnostics (Basel, Switzerland) · 2023Article
- Evaluating the value ofCancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Advanced PSMA-PET/CT Imaging Parameters in Newly Diagnosed Prostate Cancer Patients for Predicting Metastatic Disease.Cancers · 2023Article
- An exploratory study of unexplained concentration ofFrontiers in medicine · 2023Article
- Marriage of radiotracers and total-body PET/CT rapid imaging system: current status and clinical advances.American journal of nuclear medicine and molecular imaging · 2023Review
- Article
- Predictors of Bone Metastases atDiagnostics (Basel, Switzerland) · 2022Article
- Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting.La Radiologia medica · 2022Article
- PSMA PET in Imaging Prostate Cancer.Frontiers in oncology · 2022Review
- Article
- Article
- Efficacy ofQuantitative imaging in medicine and surgery · 2022Article
- Focal unspecific bone uptake on [European journal of nuclear medicine and molecular imaging · 2021Article
- Expression of neurotensin receptor-1 (NTSBreast cancer research and treatment · 2021Article
- Clinical evaluation of data-driven respiratory gating for PET/CT in an oncological cohort of 149 patients: impact on image quality and patient management.The British journal of radiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate staging is of major importance to determine the optimal treatment modality for patients with prostate cancer. Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) is a promising technique that outperformed conventional imaging in the detection of nodal and distant metastases in previous studies. However, it is still unclear whether the superior sensitivity and specificity also translate into improved patient management. The aim of this study was to assess the performance of
methodsIn this retrospective analysis, 116 patients who underwent
resultsThe primary tumour was positive on
conclusionInformation from
Indexed as
Identifiers
31802175What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.